Literature DB >> 6688397

Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.

H Ogata, S Zugarni, A Ejima, Y Kawatsu.   

Abstract

The relative bioavailability and diuretic effect of 2 commercially available tablet preparations of furosemide 40 mg was examined in 10 healthy male volunteers. A close linear relationship between the urinary excretion rate of furosemide and the rate of sodium ion excretion in urine and/or flow rate of urine was demonstrated. There were no significant differences in the urinary excretion of furosemide, sodium and potassium ions or urinary volume following the oral doses. The difference in drug content affected the urinary recovery of furosemide over 24 h but had no effect on the pharmacological response. The analytical power of ANOVA using the various parameters of the responses to furosemide was no lower than when the parameters of urinary excretion of furosemide were used.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688397     DOI: 10.1007/bf00607089

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

2.  Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.

Authors:  F Andreasen; O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of diuretics.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Bioavailability of two frusemide preparations.

Authors:  B Beermann; E Dalén; B Lindström
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

6.  Preliminary evaluation of furosemide-probenecid interaction in humans.

Authors:  D E Smith; W L Gee; D C Brater; E T Lin; L Z Benet
Journal:  J Pharm Sci       Date:  1980-05       Impact factor: 3.534

7.  Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests.

Authors:  H A Heck; S E Buttrill; N W Flynn; R L Dyer; M Anbar; T Cairns; S Dighe; B E Cabana
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

8.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Furosemide kinetics in patients with hepatic cirrhosis with ascites.

Authors:  R Fuller; C Hoppel; S T Ingalls
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.

Authors:  E Keller; G Hoppe-Seyler; R Mumm; P Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  3 in total

1.  Evaluation of statistical power function for various diclofenac bioequivalence trials with different subject numbers.

Authors:  Jovan Popović; Momir Mikov; Ana Sabo; Vida Jakovljević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.

Authors:  H Ogata; Y Kawatsu; Y Maruyama; K Machida; T Haga
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.